Link to this page
The Drug-Drug Interactions Ontology
Last uploaded:
February 11, 2016
| Id | http://purl.obolibrary.org/obo/CHEBI_49375
http://purl.obolibrary.org/obo/CHEBI_49375
|
|---|---|
| Preferred Name | dasatinib (anhydrous) |
| Synonyms |
dasatinib (anh.)
C22H26ClN7O2S
N-(2-chloro-6-methylphenyl)-2-({6-[4-(2-hydroxyethyl)piperazin-1-yl]-2-methylpyrimidin-4-yl}amino)-1,3-thiazole-5-carboxamide
anh. dasatinib
anhydrous dasatinib
dasatinibum
BMS Dasatinib
BMS-354825
N-(2-CHLORO-6-METHYLPHENYL)-2-({6-[4-(2-HYDROXYETHYL)PIPERAZIN-1-YL]-2-METHYLPYRIMIDIN-4-YL}AMINO)-1,3-THIAZOLE-5-CARBOXAMIDE
dasatinib
|
| Type | http://www.w3.org/2002/07/owl#Class |
All Properties
| prefLabel | dasatinib (anhydrous)
|
|---|---|
| label | dasatinib (anhydrous)
|
| DBSynonym | bms-354825
|
| ATCCode | L01XE06
|
| Definition | An aminopyrimidine that is 2-methylpyrimidine which is substituted at position 4 by the primary amino group of 2-amino-1,3-thiazole-5-carboxylic acid and at position 6 by a 4-(2-hydroxyethyl)piperazin-1-yl group, and in which the carboxylic acid group has been formally condensed with 2-chloro-6-methylaniline to afford the corresponding amide. A multi-targeted kinase inhibitor, it is used, particularly as the monohydrate, for the treatment of chronic, accelerated, or myeloid or lymphoid blast phase chronic myeloid leukemia. Note that the name 'dasatinib' is used to refer to the monohydrate (USAN) as well as to anhydrous dasatinib (INN).
|
| altId |
CHEBI:38943
CHEBI:49372
|
| has pharmacological target | |
| inhibits | |
| type | |
| has role | |
| InChIKey | InChIKey=ZBNZXTGUTAYRHI-UHFFFAOYSA-N
|
| is metabolised by | |
| blocks | |
| Synonym | dasatinib (anh.)
C22H26ClN7O2S
N-(2-chloro-6-methylphenyl)-2-({6-[4-(2-hydroxyethyl)piperazin-1-yl]-2-methylpyrimidin-4-yl}amino)-1,3-thiazole-5-carboxamide
anh. dasatinib
anhydrous dasatinib
dasatinibum
BMS Dasatinib
BMS-354825
N-(2-CHLORO-6-METHYLPHENYL)-2-({6-[4-(2-HYDROXYETHYL)PIPERAZIN-1-YL]-2-METHYLPYRIMIDIN-4-YL}AMINO)-1,3-THIAZOLE-5-CARBOXAMIDE
dasatinib
See more
See less
|
| xref |
CiteXplore:22411867
Reaxys:9966762
CiteXplore:18823558
CiteXplore:22992064
Wikipedia:http://en.wikipedia.org/wiki/Dasatinib
CiteXplore:23065516
CiteXplore:19494352
ChEMBL:461469
PubChem Compound:3062316
RxList:http://www.rxlist.com/cgi/generic/sprycel.htm
CiteXplore:19640584
HMDB:HMDB15384
BindingDB:13216
Patent:US7941725
Patent:US7125875
Drugs.com:http://www.drugs.com/cdi/dasatinib.html
PubChem Substance:46505143
CASRN:302962-49-8
ChemSpider:2323020
CiteXplore:17154512
PDBeChem:1N1
ChEBI:49375
CiteXplore:22740998
National Drug Code Directory:0003-0527-11
PharmGKB:PA162372878
CiteXplore:18784745
CiteXplore:18797457
KEGG DRUG:D03658
CiteXplore:19502192
Wikipedia:Dasatinib
CiteXplore:18020922
Patent:WO2010139979
CiteXplore:16775234
DrugBank:DB01254
CiteXplore:21226671
Patent:WO2010067374
See more
See less
|
| CASRN | 302962-49-8
|
| prefixIRI | obo2:CHEBI_49375
|
| is transported by | |
| related with | |
| SMILES |
CC1=NC(NC2=NC=C(S2)C(=O)NC2=C(C)C=CC=C2Cl)=CC(=N1)N1CCN(CCO)CC1
Cc1nc(Nc2ncc(s2)C(=O)Nc2c(C)cccc2Cl)cc(n1)N1CCN(CCO)CC1
|
| may interact with |
See more
See less
|
| DBname | dasatinib
|
| InChI | InChI=1S/C22H26ClN7O2S/c1-14-4-3-5-16(23)20(14)28-21(32)17-13-24-22(33-17)27-18-12-19(26-15(2)25-18)30-8-6-29(7-9-30)10-11-31/h3-5,12-13,31H,6-11H2,1-2H3,(H,28,32)(H,24,25,26,27)
|
| DBBrand | sprycel
|
| subClassOf |
| Delete | Subject | Author | Type | Created |
|---|---|---|---|---|
| No notes to display |